345 related articles for article (PubMed ID: 20919823)
1. Sunitinib for metastatic renal cell carcinoma.
Mukherji D; Larkin J; Pickering L
Future Oncol; 2010 Sep; 6(9):1377-85. PubMed ID: 20919823
[TBL] [Abstract][Full Text] [Related]
2. Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
[TBL] [Abstract][Full Text] [Related]
3. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy.
Neill MG; Wei AC; Jewett MA
Urology; 2007 Jul; 70(1):178.e9-11. PubMed ID: 17656238
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib in renal-cell carcinoma: expanded indications.
Choueiri TK; Bellmunt J
Lancet Oncol; 2009 Aug; 10(8):740. PubMed ID: 19615941
[No Abstract] [Full Text] [Related]
5. Sunitinib for the treatment of metastatic renal cell carcinoma.
Oudard S; Beuselinck B; Decoene J; Albers P
Cancer Treat Rev; 2011 May; 37(3):178-84. PubMed ID: 20817406
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
7. New challenges in kidney cancer therapy: sunitinib.
Izzedine H; Billemont B; Thibault F; Rixe O
Ann Oncol; 2007 Jul; 18 Suppl 9():ix83-6. PubMed ID: 17631600
[No Abstract] [Full Text] [Related]
8. Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma.
Aksu G; Ensaroglu F; Dolasik I; Temiz S; Halis H; Sener SY; Kaya A; Uygun K
J BUON; 2010; 15(4):798-9. PubMed ID: 21229650
[No Abstract] [Full Text] [Related]
9. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Makino K; Yoda K; Tomoishi J; Kume H
BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
[TBL] [Abstract][Full Text] [Related]
11. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
12. Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib.
Larkin J; Fisher R; Pickering L; Thway K; Livni N; Fisher C; Gore M
J Clin Oncol; 2010 Oct; 28(28):e539-40. PubMed ID: 20679595
[No Abstract] [Full Text] [Related]
13. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma.
Hutson TE
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1723-31. PubMed ID: 18928373
[TBL] [Abstract][Full Text] [Related]
15. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
16. Dose matters: the importance of appropriate dosing: a case report on sunitinib treatment in a patient with metastatic renal cell carcinoma.
Bojic M; Schmidinger M
Clin Genitourin Cancer; 2012 Dec; 10(4):277-9. PubMed ID: 22658385
[No Abstract] [Full Text] [Related]
17. Intermittent sunitinib for metastatic renal cell carcinoma.
Venkatesan P
Lancet Oncol; 2017 Mar; 18(3):e139. PubMed ID: 28163004
[No Abstract] [Full Text] [Related]
18. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
19. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma.
Narayanan S; Callis-Duffin K; Batten J; Agarwal N
Am J Med Sci; 2010 Jun; 339(6):580-1. PubMed ID: 20421784
[TBL] [Abstract][Full Text] [Related]
20. Mixed Results for Sunitinib in Renal Cancer.
Cancer Discov; 2017 Jan; 7(1):OF6. PubMed ID: 28062674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
